Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
Aristeidis Chaidos(British Society for Haematology), Anastasios Karadimitris(NIHR Imperial Biomedical Research Centre), Katerina Gouvedenou(Hammersmith Hospital), Ilaria Marigo(Hammersmith Hospital), Amin Rahemtulla(Hammersmith Hospital), Rab K. Prinjha(GlaxoSmithKline (United Kingdom)), David F. Tough(Jenner Institute), Niam Al-Mahdi(GlaxoSmithKline (United Kingdom)), Nicola Harker(GlaxoSmithKline (United Kingdom)), Irene Roberts(Hammersmith Hospital), Antonia Rotolo(University of Pennsylvania), Maurits F. Kleijnen(Hammersmith Hospital), Peter J. Tummino(Intarcia Therapeutics (United States)), Andrea Haynes(GlaxoSmithKline (United Kingdom)), Nicholas Smithers(GlaxoSmithKline (United Kingdom)), Valentina S. Caputo(Pontificia Universidad Católica de Chile), Anna K. Bassil(GlaxoSmithKline (United Kingdom)), Trevor Chapman(GlaxoSmithKline (United Kingdom)), Mohammed S. Chaudhry(Hammersmith Hospital), Olena Barbash(GlaxoSmithKline (United States)), Binbin Liu(New York State Department of Health), Nigel J. Parr(GlaxoSmithKline (United Kingdom)), Leanne Cutler(GlaxoSmithKline (United Kingdom)), Jason Witherington(GlaxoSmithKline (United Kingdom)), BaoChau Le(GlaxoSmithKline (United States))
Cited by 204
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k